# Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India

> **NCT03548337** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 301 (actual)

## Conditions studied

- Vaccines

## Interventions

- **BIOLOGICAL:** 13vPnC

## Key facts

- **NCT ID:** NCT03548337
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-31
- **Primary completion:** 2019-12-20
- **Final completion:** 2019-12-20
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03548337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03548337, "Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03548337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*